EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma

Tuan Hoang, Erica S Tsang

Journal of Gastrointestinal Cancer · 2025-12 · 56 (1)

DOI: 10.1007/s12029-024-01149-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 06.01.2025. Verfasst von Tuan Hoang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Molecular Targeted Therapy, Pancreatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 130 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Recent advances in targeted therapies have opened new avenues for intervention in PDAC, focusing on key genetic and molecular pathways that drive tumor progression. METHODS: In this review, we provide an overview on advances in novel targeted therapies in pancreatic adenocarcinoma. RESULTS: Here, we explore the latest development in targeting the KRAS pathway, a historically "undruggable" target crucial to PDAC pathogenesis. Strategies to inhibit KRAS include direct KRAS-targeted therapies, modulation of upstream and downstream signaling, KRAS-specific siRNA, and novel combination therapies integrating KRAS inhibitors with immune checkpoint blockade, PARP inhibitors, chemotherapy, CDK4/6 inhibitors, and autophagy modulators. Beyond KRAS, emerging targets such as NRG1 fusions, NTRK/ROS1 fusions, RET alterations, and the PRMT5/CDKN2A/MAT2A axis, along with EGFR and Claudin18.2 inhibitors, are also discussed as promising therapeutic strategies. Additionally, the review highlights novel approaches for microsatellite instability-high (MSIH) PDAC and emerging therapies, including adoptive cell therapies (CAR-T, TCR, TIL), cancer vaccines, and strategies to modify the tumor microenvironment. CONCLUSION: Overall, the rapid evolution of targeted therapies offers renewed optimism in the fight against pancreatic cancer, a malignancy with historically poor outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalMolecular Targeted TherapyPancreatic NeoplasmsHumansProto-Oncogene Proteins p21(ras)Tumor Microenvironment

Stichwörter der Autor:innen

CAR T-cell therapyNovel targeted therapiesPancreatic adenocarcinoma (PDAC)Proteolysis-targeting chimeras (PROTACs)

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. erica.tsang@uhn.ca.

Zitieren

APA

Hoang, T., & Tsang, E. S. (2025). Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 56(1). https://doi.org/10.1007/s12029-024-01149-w

Vancouver

Hoang T, Tsang ES. Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer. 2025;56(1). doi:10.1007/s12029-024-01149-w

BibTeX
@article{Hoang2025,
  author = {Hoang, Tuan and Tsang, Erica S},
  title = {Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2025},
  volume = {56},
  number = {1},
  doi = {10.1007/s12029-024-01149-w}
}
Kostenlos starten →